These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 3043595)

  • 1. Phase-III clinical trial of adjuvant FAM2 (5-FU, adriamycin and mitomycin C) vs control in resectable gastric cancer: a study of the EORTC Gastrointestinal Tract Cancer Cooperative Group.
    Lise M; Nitti D; Buyse M; Cartei G; Fornasiero A; Guimaraes dos Santos J; Duez N
    Recent Results Cancer Res; 1988; 110():36-43. PubMed ID: 3043595
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant FAM2 in resectable gastric cancer.
    Lise M; Nitti D; Buyse M; Marchet A; Fiorentino M; Dos Santos JG; Duez N
    Anticancer Res; 1989; 9(4):1017-21. PubMed ID: 2683987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Fluorouracil versus a combination of BCNU, adriamycin, 5-FU and mitomycin C in advanced gastric cancer: a prospective randomized study of the Italian Clinical Research Oncology Group.
    De Lisi V; Cocconi G; Tonato M; Di Costanzo F; Leonardi F; Soldani M
    Recent Results Cancer Res; 1988; 110():212-8. PubMed ID: 3136519
    [No Abstract]   [Full Text] [Related]  

  • 4. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer.
    Lise M; Nitti D; Marchet A; Sahmoud T; Buyse M; Duez N; Fiorentino M; Dos Santos JG; Labianca R; Rougier P
    J Clin Oncol; 1995 Nov; 13(11):2757-63. PubMed ID: 7595735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer.
    Chang HM; Jung KH; Kim TY; Kim WS; Yang HK; Lee KU; Choe KJ; Heo DS; Bang YJ; Kim NK
    Ann Oncol; 2002 Nov; 13(11):1779-85. PubMed ID: 12419751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined nonsimultaneous radiation therapy and chemotherapy with 5-FU, doxorubicin, and mitomycin for residual localized gastric adenocarcinoma: a Southwest Oncology Group pilot study.
    Haas CD; Mansfield CM; Leichman LP; Considine B; Bukowski RM
    Cancer Treat Rep; 1983 May; 67(5):421-4. PubMed ID: 6687837
    [No Abstract]   [Full Text] [Related]  

  • 7. An EORTC gastrointestinal (GI) group randomized evaluation of the toxicity of sequential high dose methotrexate and 5-fluorouracil combined with adriamycin (FAMTX) vs 5-fluorouracil, adriamycin and mitomycin (FAM) in advanced gastric cancer.
    Klein HO; Wils J; Bleiberg H; Buyse M; Duez N
    Med Oncol Tumor Pharmacother; 1989; 6(2):171-4. PubMed ID: 2664372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute non-lymphocytic leukemia following FAM combination adjuvant chemotherapy for gastric and lung adenocarcinoma.
    Bouillet T; Lepage E; Gisselbrecht C; Boiron M
    Nouv Rev Fr Hematol (1978); 1990; 32(3):207-9. PubMed ID: 2120675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
    Kim NK; Park YS; Heo DS; Suh C; Kim SY; Park KC; Kang YK; Shin DB; Kim HT; Kim HJ
    Cancer; 1993 Jun; 71(12):3813-8. PubMed ID: 8508349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.
    Cullinan SA; Moertel CG; Fleming TR; Rubin JR; Krook JE; Everson LK; Windschitl HE; Twito DI; Marschke RF; Foley JF
    JAMA; 1985 Apr; 253(14):2061-7. PubMed ID: 2579257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C.
    Cunningham D; Soukop M; McArdle CS; Carter DC; Smyth JF; Allan SG; Kaye SB; Sangster G; Calman KC; Hutcheon AW
    Br J Surg; 1984 Sep; 71(9):673-6. PubMed ID: 6548166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group.
    Coombes RC; Schein PS; Chilvers CE; Wils J; Beretta G; Bliss JM; Rutten A; Amadori D; Cortes-Funes H; Villar-Grimalt A
    J Clin Oncol; 1990 Aug; 8(8):1362-9. PubMed ID: 2199622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas.
    Sternberg CN; Magill GB; Sordillo PP; Cheng EW
    Am J Clin Oncol; 1984 Oct; 7(5):529-33. PubMed ID: 6391145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group.
    Allum WH; Hallissey MT; Ward LC; Hockey MS
    Br J Cancer; 1989 Nov; 60(5):739-44. PubMed ID: 2508737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277).
    Douglass HO; Lavin PT; Goudsmit A; Klaassen DJ; Paul AR
    J Clin Oncol; 1984 Dec; 2(12):1372-81. PubMed ID: 6439836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study.
    Macdonald JS; Fleming TR; Peterson RF; Berenberg JL; McClure S; Chapman RA; Eyre HJ; Solanki D; Cruz AB; Gagliano R
    Ann Surg Oncol; 1995 Nov; 2(6):488-94. PubMed ID: 8591078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FAM (5-fluorouracil, doxorubicin, and mitomycin) plus triazinate (FAM-T) in gastric carcinoma: a combined phase II trial of the Mid-Atlantic Oncology Program and the Pan American Health Organization.
    Ahlgren JD; Smith FP; Cazap E; Estevez RA; Marantz A; Woolley PV; Wilcosky T; Stein J; Schein PS
    Cancer Treat Rep; 1987 Apr; 71(4):419-20. PubMed ID: 3548959
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial.
    Allum WH; Hallissey MT; Kelly KA
    Lancet; 1989 Mar; 1(8638):571-4. PubMed ID: 2564109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy of gastric cancer: a review.
    Kelsen D
    Isr J Med Sci; 1988; 24(9-10):557-61. PubMed ID: 3060446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian Clinical Research Oncology Group (GOIRC).
    De Lisi V; Cocconi G; Tonato M; Di Costanzo F; Leonardi F; Soldani M
    Cancer Treat Rep; 1986 Apr; 70(4):481-5. PubMed ID: 3516397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.